BPSbioscience-12
넳 넲

50002 HDAC2, His-tag

Catalog #50002

Size: 50 µg
Description
Human HDAC2 , GenBank Accession No. NM_001527, full length with C-terminal His-tag, MW= 56 kDa, expressed in baculovirus expression system.
Species
Human
 
Host Species
Sf9 insect cells
 
MW
56 kDa
 
Genbank #
NM_001527
 
Tag(s)
C-terminal His-tag
 
a.a.
full length
 
UniProt #
Q92769
 
Applications
Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.
 
Stability
> 6 months at –80°C
 
Storage/Stability

>6 months at -80°C.

 
Shipping Temperature
-80°C
 
Synonym(s)
histone deacetylase 2, HDAC-2
 
Specific Activity
≥675 pmol/min/µg
 
Assay Conditions
25 mM of Tris-HCl , pH 8.0, 137 mM of NaCl, 2.7 mM of KCl, 1 mM of MgCl2, 0.1 mg/ml BSA, 20 µM substrate , BPS catalog #: 50037, and HDAC2, at 37°C, 30 min. followed by incubation with HDAC developer (Catalog #50030) for 15 min at RT. Fluorescence intensity is measured at ex360/em460.
 
Formulation
40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.2 mM KCl, 20% glycerol, 200 mM imidazole
 
Format
Aqueous buffer solution
 
References

1. Yang,W.M. et al., Proc. Natl. Acad. Sci. U.S.A. 93 (23), 12845-12850 (1996).
2. Mungall, A.J. et al., Nature 425 (6960), 805-811 (2003).

Application References:

1. Exploration of some indole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents (2017)
2. An azumamide C analogue without the zinc-binding functionality (2017)
3. Impact of binding mechanism on selective inhibition of histone deacetylase isoforms (2017)
4. Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif (2017)
5. Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation (2015) 
6. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases (2015) 
7. Tumor-suppressor role of Notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction (2015) 
8. A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy (2014) 
9. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents (2014) 
10. Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1 (2014) 
11. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014) 
12. Reassessing the effects of histone deacetylase inhibitors on hippocampal memory and cognitive aging (2014) 
13. The effect of various zinc binding groups on inhibition of histone deacetylases 1-11 (2014) 
14. Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection (2014) 
15. Class I HDAC imaging using [ (3)H]CI-994 autoradiography (2013) 
16. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests (2013) 
17. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013) 
18. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors (2013) 
19. Highly ligand efficient and selective N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin A (2013) 
20. Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with ¹⁸F-FAHA(2013) 
21. Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp (2013) 
22. Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E (2013)
23. Histone Deacetylase 11 Is an ε-N-Myristoyllysine Hydrolase (2018)
24. Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated (2018)
25. Novel hydroxamic acids incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)-3-hydroxyimino-indolin-2-ones: synthesis, biological evaluation, and SAR analysis (2018)
26. HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches (2018)
27. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors (2018)
28. Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents (2018)
29. Determination of the binding mechanism of histone deacetylase inhibitors (2018)
30. Class I Histone Deacetylase Inhibition by Tianeptinaline Modulates Neuroplasticity and Enhances Memory (2018)
31. Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status (2018)
32. Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases (2018)
33. Kinetic characterization of inhibitors of histone deacetylases (HDACs) and sirtuins,(2019)
34. A fluorine scan on the Zn2+-binding thiolate side chain of HDAC inhibitor largazole: Synthesis, biological evaluation, and molecular modeling (2019)
35. A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects (2019)
36. Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines (2020)

 

 
Warnings
Avoid freeze/thaw cycles.
 
Scientific Category
Deacetylase
版权所有： www.qwbio.com 2018-2023 北京启维益成科技有限公司
订购电话： 010-82743161 传真： 010-82743163
ꁹ后台管理